AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca's stock dipped 5.8% in August, the biggest monthly fall in 2022, raising the question whether it is a good time to buy the otherwise high-performing stock on dip. Factors like relatively better performance by healthcare stocks in the current sluggish economy and markets, the company's geographical diversification, strong pricing power, and healthy financials work in its favor.

AstraZeneca: Buy On The Dip

GlaxoSmithKline

AstraZeneca PLC (LSE:AZN) has succeeded in stopping a former senior executive from joining rival GSK PLC (LSE:GSK, NYSE:GSK) via an injunction granted by a High Court judge.  Having recently left AstraZeneca after holding several senior positions, Chris Sheldon was due to join GSK on September 1, in charge of developing the group's therapy businesses.

AstraZeneca wins injunction preventing former executive from joining GSK

AstraZeneca's (AZN) Evusheld gets approval in Japan for treating COVID-19. This is the first global approval for Evusheld as a COVID-19 treatment.

AstraZeneca (AZN) Evusheld Gets Japan Nod as COVID Treatment

Merck

Pfizer

The U.S. government expects its supply of COVID-19 vaccines and antiviral treatments to run out over the next year and is preparing for them to be sold via the commercial market, the Department of Health and Human Services said on Tuesday.

U.S. plans to move COVID vaccines, treatments to private markets in 2023

A diabetes drug developed by AstraZeneca PLC (LSE:AZN) has shown great promise in treating people with heart failure. The use of Farxiga led to ‘significantly lower risks' of hospitalisation and death, investors were told.

AstraZeneca successfully used to treat heart failure

The Japanese Ministry of Health, Labour, and Welfare approved AstraZeneca's (AZN) three marketed drugs, Lynparza, Tagrisso and Ultomiris, for three different indications in Japan.

AstraZeneca (AZN) Gets Japan Nod for Expanded Use of 3 Drugs

Thai drugmaker Siam Bioscience, owned by the country's king, reported a near 50-fold increase in annual profit in 2021, when it began producing AstraZeneca Plc's COVID-19 vaccine, government data shows.

Thai king's medical firm reports record profit after vaccine deal with AstraZeneca

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will present new data supporting its ambition to redefine cancer care at the European Society for Medical Oncology (ESMO) Congress 2022, September 9 – 13, 2022. A total of 15 approved and potential new medicines from AstraZeneca will be featured across more than 75 abstracts in 13 tumor types. Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: “At ESMO this year, new evidence will demonstrate how our medicines ar

AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022

AstraZeneca's chief executive Pascal Soriot warned on Tuesday new U.S. legislation capping drug prices would reduce the ability of companies to recoup their investment on developing new drugs and hurt innovation.

AstraZeneca's Soriot warns new U.S. drug price law will hurt innovation

AstraZeneca is interested in acquiring small and mid-sized companies specialising in oncology and cardiovascular treatments, Chief Executive Pascal Soriot said in a Reuters Newsmaker interview on Tuesday.

AstraZeneca on hunt for oncology, cardiovascular acquisitions

Johnson & Johnson

Moderna

Here is a rundown of the top pharmaceutical stocks to know about, ranked by market capitalization: Johnson & Johnson, Pfizer, Eli Lilly, AbbVie

Ups & Downs: Top Pharmaceutical Stocks Post-COVID

FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.

AstraZeneca's (AZN) Lynparza sNDA Gets FDA Priority Tag

Enhertu, AstraZeneca PLC (LSE:AZN)'s drug for women with HER2-positive breast cancer, delivered a statistically significant and clinically meaningful improvement in progression-free survival in the latest study. The DESTINY-Breast02 phase III trial pitted the AZ product against the doctors' own choice of treatment to assess efficacy.

AstraZeneca breast cancer drug performs well in latest trial

Enhertu significantly delayed breast cancer progression in trial, AstraZeneca says

TOKYO & MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Significantly Delayed Disease Progression in DESTINY-Breast02 Versus Physician's Choice of Treatment in HER2 Positive Metastatic Breast Cancer

ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician's Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer

AstraZeneca PLC (LSE:AZN) said its drug Enhertu has been given the green light in the US to be given to patients with advanced and difficult-to-treat non-small cell lung cancer. The Food & Drug Administration has approved the chemotherapy for use in people with inoperable tumours or where the cancer has spread beyond the lungs and the tumours have HER2 mutations.

AstraZeneca chemotherapy signed off for use in people with lung cancer

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with Previously Treated HER2m Metastatic Non-Small Cell Lung Cancer

ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Datopotamab Deruxtecan-Based Combinations Show Promising Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer

Datopotamab Deruxtecan-Based Combinations Show Promising Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer

AstraZeneca PLC (LSE:AZN) hailed as ‘transformational' a breast cancer treatment that has received fast-track sign-off by the US Food & Drug Administration. Enhertu, which AZ jointly developed with Japan's Daiichi Sankyo, has been approved for use in women with the HER-2 form of the disease where the tumour can't be operated on or where the cancer has spread.

AstraZeneca breast cancer drug gets the green light

AbbVie

Bristol-Myers

When the market is falling, this trio keeps rising.

3 Unstoppable Stocks That Don't Care About the Bear Market

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Approved in the U.S. as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer

ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer

Innate Pharma SA

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that a planned futility interim analysis of the INTERLINK-1 Phase 3 study sponsored by AstraZeneca (LSE/STO/Nasdaq: AZN) did not meet a pre-defined threshold for efficacy. Based on this result and the recommendation of an Independent Data Monitoring Committee, AstraZeneca has informed Innate that the study will be discontinued. There were no new

Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

Cranking out new medicines is business as usual, but these three could be big earners.

Do These 3 New Moneymakers for AstraZeneca Make It a Buy?

These stocks share several things in common.

3 Stocks We Think Could Beat the Market in the Second Half of 2022

AstraZeneca's (AZN) second-quarter results reflect a beat on both counts (revenues and earnings). AZN raises its 2022 sales growth guidance, keeping its profit forecast unchanged.

News for AstraZeneca Stock (AZN)